Glaukos (FRA:6GJ) Change In Payables And Accrued Expense : €-2.7 Mil (TTM As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is Glaukos Change In Payables And Accrued Expense?

Glaukos's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2025 was €-6.2 Mil. It means Glaukos's Accounts Payable & Accrued Expense declined by €6.2 Mil from Dec. 2024 to Mar. 2025 .

Glaukos's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was €0.0 Mil. It means Glaukos's Accounts Payable & Accrued Expense increased by €0.0 Mil from Dec. 2023 to Dec. 2024 .

Glaukos Change In Payables And Accrued Expense Historical Data

The historical data trend for Glaukos's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glaukos Change In Payables And Accrued Expense Chart

Glaukos Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

-2.21

11.02

6.81

1.20

0.02

Glaukos Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-3.33	-1.26	0.51	4.23	-6.22

Glaukos Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.7 Mil.

Glaukos Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Glaukos's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Glaukos Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Glaukos Corp (FRA:6GJ) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

GKOS:USA 6GJ:Germany

Address

One Glaukos Way, Aliso Viejo, CA, USA, 92656

Website

https://www.glaukos.com

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Glaukos Headlines

No Headlines